Our Collaboration Strategies
At BusStim, we leverage our expertise to identify and nurture high-potential biotech companies and academic research projects, with a focus on advancing groundbreaking therapies. Our collaboration strategies are centered around strategic vetting, team-building, and comprehensive support throughout the development process.
New Paragraph
Perform due diligence and rigorously vet these biotech companies and academic
research projects
Our translational and evaluation team is dedicated to selecting biotech and academic projects with the highest likelihood of success. We focus on initiatives that address critical medical needs and demonstrate a strong potential to deliver safe and effective new therapies.
We aim to cultivate a portfolio of standout companies in the biotech community. This includes curating a group of the best of the best to ensure maximum impact and innovation in our partnerships.
Management Team Development
To support our portfolio, we build or supplement management teams by bringing in key professionals with deep expertise in drug development. Our evaluation team consists of:
- An Executive/Entrepreneur in Residence
- One or two preclinical and early-stage scientists with drug development expertise in therapeutics
- At least one Clinical & Medical Professional (MD)
In many cases, our team members not only evaluate projects but also take on leadership roles such as Chief Executive Officer, Chief Business Officer, or Chief Medical Officer in these new companies to help drive the projects forward. The scientific founders will always remain a key part of the team.
Comprehensive Drug & Product Development Plans
We offer a full spectrum of support to help our partners bring new therapies to market, including:
- Animal Proof of Concept (POC) Studies: We assist in designing critical early experiments, such as in vivo POC studies and Non-Human Primate Proof of Biology, which are of great interest to early-stage investors.
- Regulatory Strategy: Our regulatory experts develop cost-efficient pathways to approval and can arrange meetings with the FDA when necessary.
- Early Clinical POC Strategy: We design fast, cost-effective strategies to establish clinical proof of concept in humans, ensuring projects move through the clinical pipeline efficiently.
Seed Funding & Milestone Roadmap
Through our extensive network, we secure equity funding from angel investors, venture capitalists, and non-dilutive grants from government agencies such as the NIH. We also organize showcase events to highlight the value and potential of our portfolio
companies. As part of our future plans, we aim to raise a dedicated Seed Fund.
Ongoing Advisory & Drug Development Support
BusStim provides ongoing leadership and advisory support throughout the drug development process. Our team serves on Joint Steering Committees (JSC) and company boards, offering guidance on all aspects of development.
Series A & B Fundraising or Research Collaborations
Once critical animal POC studies are completed, our portfolio companies are ready for the next phase of growth, including Series A fundraising or research and development collaborations with pharmaceutical companies. Our Seed Fund will serve as a feeder to these Series A investors, facilitating seamless transitions and stronger positioning for future partnerships.
Licensing or Acquisition
BusStim specializes in developing comprehensive Research and Development Operating Plans, ensuring that novel therapies are guided through key development milestones until they are ready for partnership or acquisition. Our close relationships with leading pharmaceutical companies, coupled with continuous updates on portfolio progress, position us as a trusted partner in the biotech space.
Contact Us
